-Engaged the lab members to build a high throughput discovery platform for NK cell and T cell engineering.-Developed library-based pooled screening approaches for protein, DNA, and CRISPR-based genome engineering.-Contributed to the development of novel engineered protein receptors, regulatory DNA sequences, and supportive cell therapy processes.-Oversaw a big pharma partnership to successfully deliver responsive DNA elements.

- Lead the Receptor Engineering team. We are responsible for the discovery of all CARs, TCRs, and multiple other engineered protein components for our cell therapy products. The group's workflows include binder discovery, initial protein and DNA design, virus production, cell engineering, and both screening-scale and in-depth characterization.- Discovery research lead for a preclinical stage oncology cell therapy pipeline program and co-lead for the departmental technology research strategy team.- Extensive involvement in the diligence and joint research teams with industry and academic partners.

Lead CAR discovery and early pipeline CAR screening efforts. Research lead for an early stage CART pipeline program.***Joined BMS via Celgene acquisition.

Lead CAR discovery and early screening efforts.***Joined Celgene via Juno acquisition

- Lead the early stage efforts to develop chimeric antigen receptors, from target nomination through the delivery of target-specific CARs- Oversee CAR protein binder discovery, using multiple technology platforms - Characterization of CARs and T-cell receptors discovered by high-throughput microfluidic single cell analysis platform-Development of molecular biology and NGS tools for the analysis of single cells and immune repertoires-Target identification of T-cell receptors-Engineering of immune cells for immuno-oncology assay development

***Joined Juno via AbVitro acquisition.

-Develop and optimize a microfluidic emulsion system to enable massive-scale phenotyping and pairing of immunoglobulin and T-cell receptor chain sequences from single immune cells-Discover native human disease-relevant antibodies and TCRs using AbVitro's single-cell immune cell technology platform. Particular emphasis on immuno-oncology.-Create a low-cost, high-throughput antibody protein expression and oligonucleotide conjugation pipeline-Prepare and validate target-enriched next-gen sequencing (NGS) libraries-Develop customized bioinformatic analysis for next-gen sequencing (NGS) data-Design and build proteome-scale DNA libraries for immunology-related discovery projects

-Lead technical efforts towards the creation of home-based immunoassay diagnostic to monitor medication adherence status of patients -Built scientific capabilities and demonstrated proof of concept through the development of prototype immunoassays-Coordinate with vendors/contractors to devise outsourcing plan for future development needs -Evaluate potential market opportunities for company’s technical platform

-Thesis title: “Engineered mRNA Regulation Using an Inducible Protein-RNA Aptamer Interaction”-Designed an RNA aptamer-based gene expression regulatory system and optimized its performance utilizing computational biology, in vitro, and in vivo methodology-Created intracellular RNA localization control techniques by engineering proteins, nucleic acids, and eukaryotic cells-Mentored four undergraduate students and managed oversight of their projects

-Evaluated scientific state of the new venture and recommended improvements to the industrial biotechnology company’s core cellular engineering technology-Investigated the financial opportunities for the new company by performing market research

-Characterized the cellular effects of novel kinase inhibitors in support of oncology projects-Measured the potency of novel oncology therapeutics in human tumor cell lines-Examined the mechanism of action of therapeutic candidates in cell-based assays-Analyzed cancer protein biomarkers utilizing LC-MS methodology

-Honors thesis title: “Proteomic Analysis of Gsp1p-GTP Interacting Proteins”-Investigated interactions between nucleocytoplasmic transport proteins in yeast-Led development of specific antibodies to nucleocytoplasmic proteins of interest